Table 4:

Summary of Late Events after CD19 targeted CAR-T cells

Late adverse events*	Entire cohort (N=86)	Ongoing CR (N=21)	Non-ongoing CR (N=65)	p-value**
Cytopenias (evaluated only in patients with ongoing CR and no diagnosis of subsequent MDS)	-	3/ 19 (16%)	-	-
Hypogammaglobulinemia (% of patients with available data)	28/42 (67%)	14/19 (74%)	14/ 23 (61%)	0.51
Infection density; mean number of infections/100 days at risk (Number of patients evaluated)	0.57 (53)	0.57 (20)	0.58 (33)	0.58†
Subsequent malignancies (%)				0.08
- All subsequent malignancies	13 (15%)	6 (29%)	7 (11%)
- MDS	4 (5%)	2 (10%)	2 (3%)	0.25
- non-melanoma skin cancer	6 (7%)	2 (10%)	4 (6%)	0.63
Immune-related events (%)	7 (8%)	2 (10%)	5 (8%)	1.00
Neurologic events (%)	9 (10%)	2 (10%)	7 (11%)	1.00
Patients with CVA/TIA	4 (5%)	0 (0%)	4 (5%)	0.57
Psychiatric events (%)	8 (9%)	2 (10%)	6 (9%)	1.00
GVHD (% of patients with prior allogeneic HCT)	3/15 (20%)	3/8 (38%)	0/7 (0%)	0.20

^*Number of patients with late adverse evens

^**Ongoing CR versus non-ongoing CR. P-values calculated using Fisher’s exact test.

^†P-value calculated using t-test from 100 bootstrap samples